Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10008510 | 0.86 | FUCA1 (0.56) | FUCA1P2RY14OPRL1ALDH1A1POLB | |
| SCHEMBL5402545 | 0.86 | OPRM1 (0.54) | FUCA1SIGMAR1P2RY14OPRL1 | |
| SCHEMBL30608325 | 0.85 | FUCA1 (0.49) | FUCA1SIGMAR1KMT2AP2RY14ALDH1A1 | |
| SCHEMBL5742361 | 0.85 | BCHE (0.47) | FUCA1P2RY14OPRL1 | |
| SCHEMBL5394580 | 0.85 | FUCA1 (0.46) | FUCA1P2RY14OPRL1ALDH1A1POLB | |
| SCHEMBL5742358 | 0.85 | FUCA1 (0.46) | FUCA1P2RY14OPRL1ALDH1A1POLB | |
| SCHEMBL5401139 | 0.81 | OPRM1 (0.45) | SIGMAR1KMT2APOLB | |
| SCHEMBL5409696 | 0.81 | DRD2 (0.50) | FUCA1P2RY14 | |
| SCHEMBL5406464 | 0.81 | OPRM1 (0.58) | KMT2AP2RY14ALDH1A1 | |
| SCHEMBL23700157 | 0.80 | FUCA1 (0.43) | FUCA1SIGMAR1SLC18A3P2RY14OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241887-B2 | 3-azabicyclo[3.2.1]octane derivatives | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-20040259859-A1 | 3-Azabicyclo[3.2.1]octane derivatives | PFIZER INC | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259859-A1 | 3-Azabicyclo[3.2.1]octane derivatives | OPRD1, OPRK1, OPRM1 | FUCA1 3858/4885SIGMAR1 68/4885KMT2A 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.